George Coukos

University Hospital of Lausanne — Switzerland

Immunology and Microbiology · Life Sciences

111h-index64.5kcitations863works10.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(305), Cancer Immunotherapy and Biomarkers(229), CAR-T cell therapy research(218), Immune Cell Function and Interaction(138), Monoclonal and Polyclonal Antibodies Research(71)

Publications861 total

Computational Inference of Metabolic Programs: A Case Study Analyzing the Effect of BRCA1 Loss
2025Open Access
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
500 Biomarker identification of early response and resistance to combinatorial anti-angiogenic and immune-checkpoint blockade therapy in the recurrent ovarian cancer setting
Regular and Young Investigator Award Abstracts·2025Open Access
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Cell Reports Methods·2025· 1 citedOpen Access
Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps
Trends in cancer·2025· 8 citedOpen Access
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing
Molecular Therapy Oncology·2025Open Access
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
Cancer Cell·2025· 10 citedOpen Access
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
Nature reviews. Immunology·2025· 17 cited
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer
Science Advances·2025· 3 citedOpen Access
Supplementary Figure S3 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
Supplementary Figure S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
Supplementary Figure S2 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
Supplementary Methods S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
Supplementary Table S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
Supplementary Table S2 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
Data from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
2025Open Access
79P Immune longitudinal profiling of the EORTC-1508GCG study reveals tertiary-lymphoid structures as key orchestrators of response to anti-PD-L1/anti-VEGF therapy in platinum-resistant ovarian cancer
ESMO Open·2025Open Access
Association of enrichment of CD7⁺CXCR3⁺ CAR T cells in infusion products with remission in relapsed or refractory diffuse large B-cell lymphoma.
Journal of Clinical Oncology·2025
Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure
Nature Cancer·2025· 17 citedOpen Access
Transcriptome analysis of archived tumors by Visium, GeoMx DSP, and Chromium reveals patient heterogeneity
Nature Communications·2025· 7 citedOpen Access
page 1 of 44Next →

Frequent Co-authors

Dionyssios Katsaros(8), Phyllis A. Gimotty(7), Lin Zhang(6), Daniel J. Powell(5), Joel Greshock(5), Shun Liang(5), Fabián Benencia(5), Melita Irving(5), José R. Conejo-García(4), Andrea Facciabene(4), Barbara Weber(4), Qihong Huang(4), Lana E. Kandalaft(4), David Gfeller(4), Alexandre Harari(4), Pui Cheng(3), Shuang Wei(3), Ilona Kryczek(3), Weiping Zou(3), Anil K. Sood(3)